PAXG Out in the Country

STATUS

Recruiting
End date

Jan 1, 2026
participants needed

175
sponsor

IRCCS San Raffaele

Send

Updated on 19 February 2024

See if I qualify

absolute neutrophil count

metastasis

gemcitabine

neutrophil count

paclitaxel

adenocarcinoma

pdac

pancreatic adenocarcinoma

resectable pancreatic ductal adenocarcinoma

ductal adenocarcinoma

pancreatic ductal adenocarcinoma

serum total bilirubin level

cisplatin

Summary

Show definitions

The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

Description

Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal malignancies, with a 5-year overall survival (OS) rate for all stages combined lower than 10%, decreasing to 3% in advanced disease. Additionally, PDAC is expected to become the 2nd leading cause for cancer-related death by 2030. Chemotherapy still represents the only therapeutic option in most cases, since 70% of PDAC patients exhibit metastatic or locally advanced disease at diagnosis. Concerning metastatic PDAC patients, combination chemotherapy has resulted in improved survival compared with single-agent treatment. Based on promising phase I/II studies, the PAXG regimen (cisplatin, nab-paclitaxel, capecitabine and gemcitabine) has been recommended for first-line treatment of metastatic PDAC patients in the 2019 edition of Associazione Italiana Oncologia Medica (AIOM) guidelines. Also, this regimen was approved by the Agenzia Italiana del Farmaco (AIFA) as first therapy of borderline-resectable, locally advanced and metastatic PDAC patients with good performance status (ECOG 0-1) and age 18-75 years.

Description of the intervention (schedule of visits):

All PDAC patients who are treated with PAXG regimen as first-line/primary chemotherapy at the participating institutions from January 1st 2020 to December 31st 2020 according to inclusion and exclusion criteria will be included in the present study.

Power size calculation:

The sample size will be as large as possible with a competitive enrollment. All patients treated by the PAXG regimen during 2020 in the participating institutions will be included into the trial. The investigators hypothesize that at least 175 patients (60% metastatic and 40% non-metastatic) from about 30 Italian centers will be enrolled by the end of the year. Such a sample size, or a larger one, will allow to compute in both groups a 95% confident interval of the 1-year OS with at least 10% margin of error, assuming to observe a (target) 1-year OS of 60% for metastatic patients and of 80% for non-metastatic. The trial will be considered successful if the target 1-year OS will fall into the corresponding computed 95% CI.

Details

Condition	Pancreatic Ductal Adenocarcinoma
Age	18years - 75years
Treatment	PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
Clinical Study Identifier	NCT04480268
Sponsor	IRCCS San Raffaele
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	cyto/histological diagnosis of pancreatic adenocarcinoma
	locally advanced and metastatic disease corresponding to clinical stage III-IV according to TNM 8th Ed. 2017 and borderline resectable disease as anatomically defined according to NCCN Guidelines Version 1.2020 - Pancreatic Adenocarcinoma and biologically defined according to the International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 (CA 19.9 > 500 IU/ml)
	ECOG Performance Status 1
	adequate bone marrow function (GB 3500/mm3, neutrophils 1500/mm3, platelets 100000/mm3, Hb 10 g/dl), kidney function (serum creatinine < 1.5 mg/dL) and liver function (ALT and AST < 3 ULN and Serum total bilirubin 1.5 ULN)
	Patient of child-bearing potential must agree to use two medically acceptable methods of contraception (one for the patient and one for the partner) during the study and for 4 months after the last study treatment intake for women and 6 months for men
	patients must have received at least 1 cycle (28 days) of the PAXG treatment for the disease within the timeframe starting from January 1 2020 to December 31st 2020
	patient information and signed written informed consent
Exclusion Criteria
	previous chemotherapy treatment for recurrent disease
	concurrent treatment with experimental drugs
	presence of symptomatic brain metastases
	heart failure, arrhythmia and/or acute myocardial infarction within 6 months prior to the beginning of PAXG treatment
	women on pregnancy or lactation
	history of interstitial lung disease
	history of connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, etc. )

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

0
19 Feb, 2024
1 site

Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

0
19 Feb, 2024
8 sites

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

0
19 Feb, 2024
1 site

Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study

0
19 Feb, 2024
1 site

The Role of MicroRNA in the Diagnosis Prognosis and Response to Treatment in Pancreatic Cancer

0
19 Feb, 2024
1 site

Browse trials for

absolute neutrophil count

pancreatic adenocarcinoma

resectable pancreatic ductal adenocarcinoma

ductal adenocarcinoma

pancreatic ductal adenocarcinoma

serum total bilirubin level

cisplatin

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

PAXG Out in the Country